282 related articles for article (PubMed ID: 18071704)
1. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Osako T; Ito Y; Ushijima M; Takahashi S; Tokudome N; Sugihara T; Iwase T; Matsuura M; Hatake K
Cancer Chemother Pharmacol; 2009 Apr; 63(5):865-71. PubMed ID: 18670777
[TBL] [Abstract][Full Text] [Related]
3. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
4. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
5. Capecitabine monotherapy is efficient and safe in all line settings in patients with metastatic and advanced breast cancer.
Amari M; Ishida T; Takeda M; Ohuchi N
Jpn J Clin Oncol; 2010 Mar; 40(3):188-93. PubMed ID: 19887522
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
8. Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer.
Wang HQ; Qian ZZ; Liu XM; Zhang HL; Li LF; Qiu LH; Hou Y; Zhou SY; Hao XS; Xie CH
Chin Med J (Engl); 2010 Nov; 123(22):3212-6. PubMed ID: 21163117
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of vinorelbine and capecitabine combination therapy in Chinese patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Fan Y; Xu B; Yuan P; Wang J; Ma F; Li Q; Zhang P; Li Q; Cai R
Chemotherapy; 2010; 56(4):340-7. PubMed ID: 20720418
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Ito Y; Osaki Y; Tokudome N; Sugihara T; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2009; 16(2):126-31. PubMed ID: 18807123
[TBL] [Abstract][Full Text] [Related]
12. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
13. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
15. [Single-agent Xeloda in the treatment of recurrent and metastatic breast cancer].
Wang T; Jiang ZF; Song ST; Zhang SH; Shen G; Yu JX
Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):379-81. PubMed ID: 15312353
[TBL] [Abstract][Full Text] [Related]
16. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of single agent capecitabine in pretreated metastatic breast cancer patients from the French compassionate use program.
Pierga JY; Fumoleau P; Brewer Y; Zelek L; Martin D; Turpin FL; Goudier MJ; Gil-Delgado M; Baticle JL; Namer M; Chollet P; Sutherland W; Barats JC;
Breast Cancer Res Treat; 2004 Nov; 88(2):117-29. PubMed ID: 15564795
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.
Blum JL; Dees EC; Chacko A; Doane L; Ethirajan S; Hopkins J; McMahon R; Merten S; Negron A; Neubauer M; Ilegbodu D; Boehm KA; Asmar L; O'Shaughnessy JA
J Clin Oncol; 2006 Sep; 24(27):4384-90. PubMed ID: 16926223
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
[TBL] [Abstract][Full Text] [Related]
20. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies.
Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L
Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
